EUVIMEDEUVIMED entdecken
Multizentrische Studie

Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group ( FBMTG )

Koji Nagafuji iD, Yoshikiyo Ito, Toshihiro Miyamoto, Tetsuya Eto, Tomohiko Kamimura, Koji Kato, Yasuhiko Miyazaki, Atsuhi Wake, Kentaro Kohno, Ken Takase, Yutaka Imamura, Naoyuki Uchida und 8 weitere

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14407 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Koji Nagafuji und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan. Hauptthemen laut MEDLINE: Dasatinib, Fusion Proteins, bcr-abl, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess the efficacy of continuous dasatinib in improving outcomes for adult patients with BCR::ABL1 ALL.

Methods

The prospective, multicenter ALL/MRD2014 trial introduced a modified protocol compared to the MRD2008 trial, incorporating continuous dasatinib use and reduced chemotherapy intensity.

Results

Among the 164 adult ALL patients enrolled (2014–2019), 61 were Philadelphia‐positive (Ph+) (median age 50 years; 38 males, 23 females). Post‐induction, 96.7% achieved complete remission (CR). The 3‐year event‐free survival (EFS) and overall survival (OS) were 51% and 76%, respectively. Patients undergoing allo‐HSCT in CR1 had improved outcomes, with a 3‐year EFS of 64% and OS of 87%. MRD‐negative patients before transplantation exhibited superior survival (EFS: 71% vs. 29%; OS: 94% vs. 57%). Comparison with the MRD2008 trial revealed similar outcomes, with the MRD2014 trial achieving a 3‐year EFS of 51% and OS of 76% vs. 52% and 84% in MRD2008. Although not statistically significant, the MRD2014 trial showed trends of increased relapse (CIR: 39% vs. 26%, p = 0.305) and reduced non‐relapse mortality (NRM: 10% vs. 21%, p = 0.181).

Conclusion

The ALL/MRD2014 trial underscores the importance of MRD status and allo‐HSCT in Ph+ ALL. Continuous dasatinib‐based regimens offer favorable outcomes in MRD‐negative patients. Trial Registration This study was registered with the UMIN Clinical Trials Registry (UMIN‐CTR), number UMIN000012382

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DasatinibFusion Proteins, bcr-ablPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsHumansMaleFemaleMiddle AgedAdultPrognosisAgedProspective StudiesYoung AdultHematopoietic Stem Cell TransplantationTreatment OutcomeNeoplasm, ResidualAdolescentAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

BCR::ABL1Philadelphia chromosomeacute lymphoblastic leukemiadasatinibtyrosine kinase inhibitor

Substanzen

DasatinibFusion Proteins, bcr-ablProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Hematology & Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
  • Hematology/Respiratory Medicine, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
  • Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
  • Department of Hematology, HaraSanshin General Hospital, Fukuoka, Japan.
  • Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.

ORCID-Profile: Koji Nagafuji

Zitieren

APA

Nagafuji, K., Ito, Y., Miyamoto, T., Eto, T., Kamimura, T., Kato, K., Miyazaki, Y., Wake, A., Kohno, K., Takase, K., Imamura, Y., Uchida, N., Tanimoto, K., Kawano, N., Kurokawa, T., Kondo, Y., Fujisaki, T., Tsukada, J., Yonemoto, K., & Akashi, K. (2025). Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group ( FBMTG ). European Journal of Haematology. https://doi.org/10.1111/ejh.14407

Vancouver

Nagafuji K, Ito Y, Miyamoto T, Eto T, Kamimura T, Kato K, et al. Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group ( FBMTG ). European Journal of Haematology. 2025. doi:10.1111/ejh.14407

BibTeX
@article{Nagafuji2025,
  author = {Nagafuji, Koji and Ito, Yoshikiyo and Miyamoto, Toshihiro and Eto, Tetsuya and Kamimura, Tomohiko and Kato, Koji and Miyazaki, Yasuhiko and Wake, Atsuhi and Kohno, Kentaro and Takase, Ken and Imamura, Yutaka and Uchida, Naoyuki and Tanimoto, Kazuki and Kawano, Noriaki and Kurokawa, Toshiro and Kondo, Yukio and Fujisaki, Tomoaki and Tsukada, Junichi and Yonemoto, Koji and Akashi, Koichi},
  title = {Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group ( FBMTG )},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14407}
}
Kostenlos starten →